Back To: Home : Featured Technology : Gene and Cell Therapies

CLICK HERE FOR WHAT'S NEW IN:
 

OSE to explore myeloid cell targets
September 2019
SHARING OPTIONS:

NANTES, France—The French National Research Agency (ANR) has selected OSE Immunotherapeutics’ DC-TARGET project as a recipient for a grant worth up to €800,000 as part of the AAPG 2019 call for proposals. The program is coordinated by Dr. Christophe Caux, who leads a research team at the Cancer Research Center and Cancer Immunotherapy Laboratory of Lyon. The program seeks to identify new targets of interest expressed by myeloid cells, suppressive immune cells implicated in tumor immune escape and cell invasion. The role of each cell will be characterized by single-cell RNAseq and gene editing, and the Bioinformatics platform will be used to analyze the data generated. After targets have been identified and validated, OSE will work to develop specific monoclonal antibodies capable of blocking the identified targets. Triple negative breast cancer will be a key focus in this program.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.